Back to top

gene-editing: Archive

Zacks Equity Research

EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y

Editas stock jumps 16% on reporting a narrower-than-expected Q4 loss and beating revenue estimates while advancing its EDIT-401 gene-editing candidate toward its first human study in 2026.

CPRXNegative Net Change USNANegative Net Change EDITPositive Net Change ALXOPositive Net Change